Company Performance - Cellectar Biosciences, Inc. (CLRB) has gained approximately 12.6% year-to-date, outperforming the average gain of 4.9% in the Medical sector [4] - The Zacks Consensus Estimate for CLRB's full-year earnings has increased by 6.5% over the past quarter, indicating improving analyst sentiment [3] - Cellectar Biosciences, Inc. is currently ranked 2 (Buy) in the Zacks Rank system, suggesting a favorable outlook for the stock [3] Industry Comparison - Cellectar Biosciences, Inc. belongs to the Medical - Products industry, which has seen an average gain of 7.5% year-to-date, indicating that CLRB is performing better than its industry peers [5] - Another stock in the Medical sector, Cencora (COR), has also outperformed the sector with a year-to-date gain of 16.2% [4] - The Medical sector as a whole is ranked 4 in the Zacks Sector Rank, which evaluates the strength of various groups within the sector [2]
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?